Advanced Proteome Therapeutics Corporation announced the appointments of two new members to its Scientific Advisory Board (SAB): Dr. Aditya Bardia, a board-certified medical oncologist, is an Attending Physician at Massachusetts General Hospital Cancer Center (MGHCC), Harvard Medical School, Boston, and Dr. Greg Thurber, is a member of the Faculty of Chemical Engineering and Biomedical Engineering at the University of Michigan. Dr. Bardia, who is Director of the Precision Oncology Program at the MGH Center for Breast Cancer. He has been the principal investigator of several clinical trials related to novel therapies in breast cancer, including antibody-drug conjugates such as sacituzumab govitecan (IMMU-132) that was given breakthrough designation status by the FDA in 2016. Dr. Bardia is co-leader of the Molecular and Precision tumor board at MGHCC, and an editorial board member of the American Society of Clinical Oncology (ASCO), Tumor Board. Dr. Thurber’s work involves applying fundamental biotransport principles to design novel therapeutics and molecular imaging agents and developing an understanding of the critical factors that govern the distribution of agents, such as antibody-drug conjugates, in cells and tissues, to optimize their efficacies. Many thanks are also due to Drs. Stephen Hanessian, Isis Pharmaceuticals Research Chair in Medicinal Chemistry at the Universite de Montreal and Steven Withers, Canada Research Chair in Chemical Biology at the University of British Columbia for serving on the SAB since the inception of the Company and making available their capabilities in the design and discovery of novel therapeutics.